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A b s t r a c t
Background: Post-implantation paravalvular leak (PVL) remains a significant complication of transcatheter aortic valve im-
plantation (TAVI). More importantly, its occurrence may impact long-term mortality. 
Aim: We sought to evaluate the effects of balloon post-dilatation (PD) on the reduction of PVL and mortality in patients 
undergoing TAVI. 
Methods: A total of 101 consecutive patients undergoing TAVI were enrolled. Angiography, echocardiography, and the aortic 
regurgitation index (ARI) were used to assess the severity of PVL before and after balloon PD. Patients were divided into two 
groups based whether or not PD after TAVI was performed. Reduction of PVL, change of ARI, and clinical outcomes were 
assessed. 
Results: Balloon post-dilatation was performed in 23 (22.8%) patients. In 95.6%, PVL reduction was successful (no or mild 
PVL). PD increased the ARI from 23.4% (22.4–24.0) to 27.1% (26.1–28.3); p < 0.001. Thirty-day mortality rate was 14.1% 
in the PD (–) group vs. 0.0% in the PD (+) group; p = 0.07. One-year mortality (21.8% vs. 4.3%, p = 0.97) and procedural 
stroke rate (7.7% vs. 8.7%, p = 0.99) were not different between the groups. 
Conclusions: Balloon post-dilatation may be a safe and effective technique to reduce moderate to severe PVL after TAVI.
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INTRODUCTION
Transcatheter aortic valve implantation (TAVI) is a less in-
vasive treatment option for elderly, high-risk patients with 
symptomatic severe aortic stenosis (AS) than surgical aortic 
valve replacement. TAVI improves survival and quality of life 
in inoperable patients as compared to medical treatment of 
severe AS [1–3]. However, post-implantation paravalvular 
leak (PVL) remains a significant TAVI-related complication 
[4]. Importantly, the presence of PVL may worsen clinical 
outcomes of patients undergoing TAVI [5]. It is present in up 
to 70% of all patients undergoing TAVI, and more than mild 
PVL has been reported in about 10–15% of all TAVI patients 
[1, 6–14]. Angio graphy and echocardiography are useful tools 
to quantify the degree of PVL immediately after deployment of 
the prosthesis and can be used to identify patients who might 
benefit from optimisation techniques. Combining invasive 
haemodynamic measurements with assessment of the aortic 
regurgitation index (ARI) and imaging may be even more ac-
curate than imaging alone [9, 15, 16]. Balloon post-dilatation 
(PD) can reduce PVL by achieving a better expansion of the 
prosthesis and optimal sealing of the paravalvular space. 
Valve-in-valve implantation is another option to overcome 
significant PVL, especially if the implantation position is more 
deep or more shallow than expected [17–19]. However, data 
on the impact of PD on long-term outcomes after TAVI are 
scarce. The aim of our study was to evaluate whether balloon 
PD is safe and effective in reducing PVL after TAVI and to 
assess its impact on mortality. 
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METHODS
A total of 101 consecutive high-risk elderly patients with severe 
symptomatic AS undergoing TAVI were enrolled between 
November 2008 and November 2014. Patient screening 
and selection was performed by a multidisciplinary Heart 
Team supported by clinical and imaging resources. TAVI 
procedures were performed using Edwards Sapien, Edwards 
Sapien XT, Edwards Sapien 3 (Edwards Lifesciences, Irvine, 
USA) Medtronic Corevalve, EvolutR (Medtronic Inc., Minne-
apolis, USA), and JenaValve (JenaValve Technology, Munich, 
Germany). Access routes were transfemoral, transapical, and 
direct aortic. Procedures were performed under general 
anaesthesia or sedation. Balloon aortic valvuloplasty was per-
formed in each case. Baseline characteristics, and procedural 
and outcomes data was collected and analysed prospectively. 
After valve deployment, the degree of PVL was routinely as-
sessed by aortic root angiography (30 mL contrast dye at a flow 
rate of 15 mL/s) according to the visually estimated density 
of opacification of the left ventricle (LV) into three degrees 
adapted from the VARC-2 criteria: mild (reflow of contrast in 
the outflow tract and middle portion of the LV but clearing 
with each beat), moderate (reflow of contrast in the whole 
LV cavity with incomplete washout in a single beat and faint 
opacification of the entire LV over several cardiac cycles), and 
severe (opacification of the entire LV with the same intensity 
as in the aorta and persistence of the contrast after a single 
beat) and with echocardiography [20]. In all patients, a 6 Fr 
pigtail catheter was placed approximately 2 cm above the 
aortic valve. In all patients, haemodynamics were assessed and 
calculation of the ARI was performed to quantify the extent of 
PVL more precisely and to have a point of reference before 
PD was carried out. The ARI was calculated according to the 
following formula: ([diastolic blood pressure – left ventricular 
end-diastolic pressure]/systolic blood pressure) × 100%, from 
5 to 10 min after valve deployment or PD. A detailed descrip-
tion of ARI assessment and its limitations were described pre-
viously [9]. In patients with more than mild angiographically 
detected PVL and/or an ARI < 25%, PVL was evaluated by 
echocardiography, preferably transesophageal echocardio-
graphy, and if confirmed, a PD was performed. In patients 
with suboptimal frame expansion causing more than mild 
PVL, PD was performed to obtain a better expansion of the 
prosthesis stent frame and a better sealing of the paravalvular 
space. PD was performed by adding 1–2 cc of contrast dye to 
the delivery system of balloon expandable valves used during 
TAVI. For self-expandable prostheses, a 1:1 balloon to aortic 
native annulus was used for PD (Osypka VACS II, Osypka AG, 
Germany). The primary endpoint of our study was the change 
of the PVL grade and ARI after PD in patients undergoing 
TAVI. Secondary endpoints were the severity of PVL defined 
according to the VARC-2 criteria, all-cause mortality at 30 days 
and one year, and post-procedural stroke rate. Patients were 
divided into two groups based whether or not balloon PD 
after TAVI was performed. The study protocol was approved 
by the institutional Ethical Board.
Statistical analysis
Results are presented as numbers of patients (percentages) 
or the median (interquartile range [IQR]) where applicable. 
Differences between groups were tested using c2 test and 
the Fisher’s exact test for dichotomous variables, and the 
Mann-Whitney U-test for continuous variables. Changes 
in the ARI between pre, immediately after, and post TAVI 
were analysed with Wilcoxon signed-rank test. Changes in 
the proportions of patients with none, mild, moderate, and 
severe PVL between pre, immediately after, and post TAVI 
were tested with c2 test. In addition, changes in the propor-
tions of patients with “none/mild” vs. “moderate/severe” 
PVL were analysed using McNemar’s test. The difference in 
mortality between patients with and without PD after TAVI 
during 12-month follow-up was assessed by the Kaplan-Meier 
method and log-rank test. All tests were two-tailed, and 
a p value < 0.05 was considered statistically significant. All sta- 
tistical analysis was performed using SPSS 15.0 (SPSS, Inc., 
Chicago, IL, USA).
RESULTS
A total of 101 consecutive patients underwent TAVI. Baseline 
characteristics are shown in Table 1. PD was performed in 
23 (22.8%) patients. Patients were divided based on the need for 
PD into two groups: with [PD (+), 23 patients] and without PD 
[PD (–), 78 patients]. Procedural data are summarised in Table 2. 
No annular rupture was observed in the PD (+) group. The 
transfemoral access was used in 73.1% of patients in the PD (–) 
group and in 91.3% in the PD (+) group (p < 0.001). Inter-
estingly, the fluoroscopy time, radiation dose, and contrast 
medium volume were higher in patients without PD (Table 2). 
No difference in the size of prosthesis, annulus dimensions, 
and cover index between groups was found. In 95.6% of pa-
tients PVL reduction was successful (no or mild PVL). Detailed 
data presenting severity of PVL before and immediately after 
prosthesis deployment and at the end of the TAVI procedure 
after PD is shown in Figure 1A (for all patients) and Figure 1B 
(for patients requiring PD). PD increased the ARI from 23.4% 
(22.4–24.0) to 27.1% (26.1–28.3); p < 0.001. No coronary 
obstruction in the PD (+) group was noted. A trend towards 
increased 30-day mortality was observed in the PD (–) group 
(14.1% vs. 0.0%; p = 0.07). In contrast, no differences in 
stroke (7.7% vs. 8.7%; p = 0.99) and myocardial infarction 
(3.8% vs. 4.3%; p = 0.99) rates were observed. One-year 
mortality rate (21.8% vs. 4.3%, p = 0.07, Fig. 2) was higher 
in the PD (–) group, but no statistical significance was found.
We also performed a subanalysis of balloon-expandable 
valves (Edwards and Jena Valve) vs. self-expandable valves 
(Corevalve) in terms of PVL occurrence after prosthesis deploy-
ment, PD, and access site. More than mild PVL after prosthesis 
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deployment, after PD, and at the end of TAVI procedure were 
present in 16 (19.8%), 16 (19.8%), and two (2.5%) patients in 
the balloon expandable valves group vs. eight (40.0%), seven 
(35.0%), and four (20.0%) patients in the self-expanding valves 
group (p = 0.08; p = 0.23; p = 0013), respectively. 
DISCUSSION
Many factors may contribute significantly to clinical outcomes 
after TAVI. For instance, the presence of coronary artery disease 
and the occurence periprocedural ischaemic complications 
may worsen clinical outcomes [21, 22]. Another potential factor 
is the presence of PVL after TAVI. Importantly, PVL remains the 
factor linked directly to the procedure itself. Moderate-to-severe 
PVL had been previously identified as an independent predic-
tor of death between 30 days and one year after TAVI with 
Medtronic CoreValve [23]. An impact of PVL on medium-term 
prognosis has recently been demonstrated also for the Edwards 
SAPIEN prosthesis [7]. Meta-analyses of multiple studies in the 
high-risk populations showed that moderate or severe PVL is an 
important determinant of mortality regardless of the implanted 








Age, median (IQR) [years] 81.0 (76.0–84.0) 81.0 (77.0–84.0) 82.0 (72.5–84.0) 0.80
Age ≥ 80 years 59 (58.4%) 46 (59.0%) 13 (56.5%) 0.83
Men 40 (39.6%) 31 (39.7%) 9 (39.1%) 0.96
Body mass index, median (IQR) [kg/m2] 28.0 (25.2–31.1) 27.9 (25.6–30.6) 27.8 (25.6–31.3) 0.95
eGFR median, (IQR) [mL/min/1.73 m2] 61.0 (39.0–81.0) 60.0 (43.0–76.5) 70.0 (43.5–81.0) 0.32
NYHA class: 0.019
I 0 (0.0%) 0 (0.0%) 0 (0.0%)
II 17 (16.8%) 9 (11.5%) 8 (34.8%)
III 74 (73.3%) 62 (79.5%) 12 (52.2%)
IV 10 (9.9%) 7 (9.0%) 3 (13.0%)
Arterial hypertension 94 (93.1%) 71 (91.0%) 23 (100.0%) 0.35
Diabetes mellitus 35 (34.7%) 28 (35.9%) 7 (30.4%) 0.80
Atrial fibrillation 35 (34.7%) 24 (30.8%) 11 (47.8%) 0.13
History of MI 31 (30.7%) 25 (32.1%) 6 (26.1%) 0.59
PCI 29 (28.7%) 21 (26.9%) 8 (34.8%) 0.46
CABG 17 (16.8%) 14 (17.9%) 3 (13.0%) 0.76
Chronic total occlusion 9 (8.9) 9 (11.5) 0 (0.0) 0.11
COPD 12 (11.9%) 9 (11.5%) 3 (13.0%) 0.99
Stroke/transient ischaemic attack 10 (9.9%) 9 (11.5%) 1 (4.3%) 0.45
Pacemaker 11 (11.1%) 10 (13.2%) 1 (4.3%) 0.45
Logistic Euroscore I, median (IQR) [%] 14.0 (10.0–22.5) 17.0 (10.0–23.0) 11.0 (8.0–14.5) 0.08
STS, median (IQR) [%] 12.0 (5.0–24.0) 9.0 (5.0–20.0) 21.0 (8.5–30.0) 0.13
TG max, median (IQR) [mm Hg] 87.0 (71.5–108.0) 87.0 (70.5–106.5) 79.5 (62.0–90.0) 0.19
TG mean, median (IQR) [mm Hg] 51.0 (42.5–66.5) 52.0 (43.0–65.0) 48.5 (38.0–52.0) 0.26
AVA, median (IQR) [cm2] 0.6 (0.4–0.8) 0.7 (0.6–0.8) 0.8 (0.6–1.0) 0.20
LVEF, median (IQR) [%] 60.0 (47.5–65.0) 60.0 (47.0–65.0) 62.0 (48.0–65.0) 0.51
Aortic regurgitation: 0.11
0 35 (34.7%) 24 (30.8%) 11 (47.8%)
1 51 (50.5%) 44 (56.4%) 7 (30.4%)
2 14 (13.9%) 9 (11.5%) 5 (21.7%)
3 1 (1.0%) 1 (1.3%) 0 (0.0%)
AVA — aortic valve area; CABG — coronary artery bypass graft; COPD — chronic obstructive pulmonary disease; eGFR — estimated glomerular 
filtration rate; IQR — interquartile range; LVEF — left ventricular ejection fraction; MI — myocardial infarction; NYHA — New York Heart Association; 
PCI — percutaneous coronary intervention; STS — The Society of Thoracic Surgeons; TG — transvalvular gradient
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valve type [24, 25]. The occurrence of PVL after TAVI might be 
more frequent after direct valve implantation without balloon 
PD, resulting in more frequent PD afterwards [12].
We confirmed that balloon PD can effectively and safely 
reduce the degree of PVL after TAVI when the primary result 
of the implantation of the prosthesis is not optimal. PD has 
been performed due to frame under-expansion in most cases, 
and it was required in 22.7% of patients. This rate was quite 
similar to that reported in previous studies with a post-dilation 
rate of 30% to 38% after implantation of self-expanding pros-
theses and 28% to 41% for balloon-expandable valves [15, 
17, 23, 24, 26]. PD might be associated with a higher rate of 
cardiovascular complications, conduction disturbances, an-
nulus rupture, coronary obstruction, and cerebral embolism 
leading to stroke [1, 4]. These findings were not confirmed in 
our study because no differences in cardiovascular complica-
tions such as coronary obstruction, stroke, and death were 
observed. Interestingly, a trend towards improved mortality 
in patients with PD was noted. However, worse short- and 
long-term outcomes in patients without PD are possibly re-
lated to higher rates of blood transfusion and overall higher 
risk profile (logistic Euroscore I, NYHA class).
Post-implantation PVL is routinely assessed by control 
aortography and quantified according to VARC-2 criteria 
[20]. Echocardiography is helpful to identify the mechanism 
of PVL such as suboptimal frame expansion due to severe 
calcification in the native valve. The accurate assessment of 
PVL is an important means for determining the effectiveness 
of procedure. To quantify PVL grade more accurately, besides 
angiography and echocardiography, we used the previously 
validated ARI, for which a cut-off value of 25 has been shown 
to be an independent predictor of one-year mortality after 








Transfemoral access 78 (77.2%) 57 (73.1%) 21 (91.3%) < 0.001
Transapical access 21 (20.8%) 21 (26.9%) 0 (0.0%)
Transaortic access 2 (2.0%) 0 (0.0%) 2 (8.7%)
Medtronic CoreValve 20 (19.8%) 13 (16.7%) 7 (30.4%) 0.22
Edwards SAPIEN 77 (76.2%) 61 (78.2%) 16 (69.6%)
Jena Valve 4 (4.0%) 4 (5.1%) 0 (0.0%)
Prosthesis size: 0.86
23 mm 16 (15.8%) 14 (17.9%) 2 (8.7%)
25 mm 2 (2.0%) 2 (2.6%) 0 (0.0%)
26 mm 48 (47.5%) 36 (46.2%) 12 (52.2%)
27 mm 1 (1.0%) 1 (1.3%) 0 (0.0%)
29 mm 29 (28.7%) 21 (26.9%) 8 (34.8%)
31 mm 5 (5.0%) 4 (5.1%) 1 (4.3%)
Prosthesis size, median (IQR) [mm] 26.0 (26.0–29.0) 26.0 (26.0–29.0) 26.0 (26.0–29.0) 0.35
Annulus size, median (IQR) [mm] 23.0 (22.0–25.0) 23.0 (21.8–25.0) 23.0 (22.0–24.8) 0.50
Cover index, median (IQR) [%] 11.5 (8.7–15.4) 11.5 (8.7–15.3) 13.5 (10.3–15.4) 0.33
Ellipticity index, median (IQR) [%] 1.2 (1.0–1.2) 1.2 (1.0–1.2) 1.2 (1.0–1.3) 0.77
AR index before, median (IQR) [%] 28.4 (25.0–29.9) 29.4 (27.9–30.5) 23.4 (22.4–24.0) < 0.001
AR index before < 25% 25 (24.8%) 4 (5.1%) 21 (91.3%) < 0.001
AR index after, median (IQR) [%] 27.1 (26.1–28.3) – 27.1 (26.1–28.3) –
AR index after < 25% 1 (0.9%) – 1 (4.3%) –
Radiation dose, median (IQR) [mGy] 733.0 (634.0–831.5) 783.0 (678.0–841.0) 631.0 (606.0–739.5) < 0.001
Contrast medium load, median (IQR) [mL] 100.0 (75.0–150.0) 100.0 (100.0–150.0) 75.0 (75.0–75.0) < 0.001
Fluoroscopy time, median (IQR) [min] 14.0 (13.0–15.5) 14.0 (13.0–16.0) 13.0 (12.0–14.0) 0.013
TG max after TAVI, median (IQR) [mm Hg] 14.5 (10.8–19.0) 14.0 (10.6–19.0) 14.0 (10.0–19.0) 0.93
TG mean after TAVI, median (IQR) [mm Hg] 8.0 (6.0–10.0) 8.0 (6.0–9.6) 7.5 (6.0–11.0) 0.75
LVEF after, median (IQR) [%] 49.0 (42.8–60.0) 50.0 (44.0–60.0) 47.0 (38.5–49.5) 0.09
AR — aortic regurgitation; IQR — interquartile range; LVEF — left ventricular ejection fraction; TAVI — transcatheter aortic valve implantation;  
TG — transvalvular gradient
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Figure 2. Kaplan–Meier curves for survival for patients strati-
fied by the need for balloon post-dilatation (PD)
Figure 1. Severity of paravalvular leak (PVL) before and immediately after prosthesis deployment and at the end of the transcat-
heter aortic valve implantation (TAVI) procedure; A. For all patients; B. For patients requiring balloon post-dilatation); *p-value 
from c2 test; **p-value from McNemar’s test for changes in the proportions of patients with “none/mild” vs. “moderate/severe” PVL
TAVI [9]. The ARI is a useful parameter to identify the need 
of PD but also to quantify the success of PD (additionally to 
imaging modalities) [9, 15]. Moreover, recently Sinning et al. 
[27] have shown that ARI integrating pre- and post-procedural 
haemodynamic status increases the discriminatory value of 
post-procedural ARI and is useful to identify patients with 
unfavourable prognosis. The difference in radiation dose, 
fluoroscopy time, and contrast load between patients with 
and without PD may be caused by some differences in base-
line characteristics and more frequent use of the transapical 
approach in the PD (+) group. 
Limitations of the study
The present investigation represents a single-centre experi-
ence with a relatively small sample size, which could be 
regarded as a limitation of the study. Because the study was 
not randomised we can expect some important differences in 
baseline characteristics between the two groups, which may 
influence mortality as well as other clinical outcomes. The 
limited sample size did not allow us to use a propensity 
matching technique to control for selection bias. Thus, the 
results, especially in terms of clinical outcomes, should be 
considered exploratory and hypothesis generating. The 
ARI might be confounded by high systemic blood pressure, 
diastolic dysfunction, myocardial ischaemia during and after 
valve deployment or PD, as well as the use of vasopressors 
during TAVI, and other causes that may lead to an increase 
of LV end-diastolic pressure leading to false positive ARI. 
Likewise, the heart rate and its undeniable influence on the 
diastolic aortic blood pressure affects the ARI. In spite of sev-
eral limitations, our study represents the complete analysis of 
consecutive patients without any exclusion criteria and with 
follow-up data available for all patients.
CONCLUSIONS
Balloon post-dilatation may be safe and effective technique 
to reduce moderate to severe PVL after TAVI.
Conflict of interest: none declared
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Wpływ doprężenia na zmniejszenie przecieku 
okołozastawkowego i śmiertelność  
po przezskórnej implantacji zastawki aortalnej
Paweł Kleczyński, Artur Dziewierz, Marzena Daniec, Maciej Bagieński, Łukasz Rzeszutko,  
Danuta Sorysz, Jarosław Trębacz, Robert Sobczyński, Marek Tomala, Dariusz Dudek
Instytut Kardiologii, Uniwersytet Jagielloński, Collegium Medicum, Kraków
S t r e s z c z e n i e
Wstęp: Przeciek okołozastawkowy (PVL) jest jednym z istotnych powikłań po zabiegu przezskórnej implantacji zastawki 
aortalnej (TAVI) i może wpływać na rokowanie odległe pacjentów.
Cel: Celem niniejszej pracy była ocena efektów doprężenia balonem (PD) na stopień PVL i śmiertelność u pacjentów po TAVI.
Metody: Do badania włączono 101 pacjentów po TAVI. Do oceny PVL użyto parametrów angiograficznych, echokardio-
graficznych i wskaźnika niedomykalności aortalnej (ARI). Pacjentów podzielono na dwie grupy, w zależności od tego, czy 
wykonano doprężenie. Oceniano stopień redukcji PVL, ARI i śmiertelność.
Wyniki: Doprężenie balonem wykonano u 23 (22,8%) pacjentów. W 95,6% przypadkach redukcja PVL była skuteczna (brak 
lub mały PVL). Odnotowano wzrost ARI z 23,4% (22,4–24,0) do 27,1% (26,1–28,3); p < 0,001. 30-dniowa śmiertelność 
wyniosła 14,1% w grupie PD (–) vs. 0,0% w grupie PD (+); p = 0,07. Śmiertelność po 12 miesiącach (21,8% vs. 4,3%; 
p = 0,97) i częstość udaru związanego z zabiegiem (7,7% vs. 8,7%; p = 0,99) nie były statystycznie różne między grupami.
Wnioski: Doprężenie balonem może być bezpieczną i skuteczną techniką służącą do zmniejszenia stopnia PVL po TAVI.
Słowa kluczowe: stenoza aortalna, przezskórna implantacja zastawki aortalnej, przeciek okołozastawkowy, postdylatacja
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